Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study

@article{Pettengell2008MultivariateAO,
  title={Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study},
  author={Ruth Pettengell and Andr{\'e} Bosly and Thomas D. Szucs and Christian Jackisch and Robert D. Leonard and Robert J. Paridaens and Manuel Constenla and Matthias Schwenkglenks},
  journal={British Journal of Haematology},
  year={2008},
  volume={144},
  pages={677 - 685}
}
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy. Identifying patients most at risk of developing FN might help physicians to target prophylactic treatment with colony-stimulating factor (CSF), in order to decrease the incidence, or duration, of myelosuppression and facilitate delivery of chemotherapy as planned. We present a risk model for FN occurrence in the first cycle of chemotherapy… CONTINUE READING
35 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

patients receiving systemic chemotherapy

  • T. J. Smith, J. Khatcheressian, +19 authors A. C. Wolff
  • 2006
Highly Influential
10 Excerpts

A validated risk model for early neutropenic events in older cancer patients receiving systemic chemotherapy

  • M. Shayne, E. Culakova, +4 authors G. Lyman
  • Journal of Clinical Oncology,
  • 2007
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…